Literature DB >> 10496886

Local and systemic neutralizing antibody responses induced by intranasal immunization with the nontoxic binding domain of toxin A from Clostridium difficile.

S J Ward1, G Douce, G Dougan, B W Wren.   

Abstract

Fourteen of the 38 C-terminal repeats from Clostridium difficile toxin A (14CDTA) were cloned and expressed either with an N-terminal polyhistidine tag (14CDTA-HIS) or fused to the nontoxic binding domain from tetanus toxin (14CDTA-TETC). The recombinant proteins were successfully purified by bovine thyroglobulin affinity chromatography. Both C. difficile toxin A fusion proteins bound to known toxin A ligands present on the surface of rabbit erythrocytes. Intranasal immunization of BALB/c mice with three separate 10-microg doses of 14CDTA-HIS or -TETC generated significant levels of anti-toxin A serum antibodies compared to control animals. The coadministration of the mucosal adjuvant heat labile toxin (LT) from Escherichia coli (1 microg) significantly increased the anti-toxin A response in the serum and at the mucosal surface. Importantly, the local and systemic antibodies generated neutralized toxin A cytotoxicity. Impressive systemic and mucosal anti-toxin A responses were also seen following coadministration of 14CDTA-TETC with LTR72, an LT derivative with reduced toxicity which shows potential as a mucosal adjuvant for humans.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10496886      PMCID: PMC96861          DOI: 10.1128/IAI.67.10.5124-5132.1999

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  51 in total

1.  Toxin A of Clostridium difficile is a potent cytotoxin.

Authors:  K D Tucker; P E Carrig; T D Wilkins
Journal:  J Clin Microbiol       Date:  1990-05       Impact factor: 5.948

2.  Antigenic cross-reactivity and functional inhibition by antibodies to Clostridium difficile toxin A, Streptococcus mutans glucan-binding protein, and a synthetic peptide.

Authors:  B W Wren; R R Russell; S Tabaqchali
Journal:  Infect Immun       Date:  1991-09       Impact factor: 3.441

3.  Nucleotide sequence of Clostridium difficile toxin B gene.

Authors:  L A Barroso; S Z Wang; C J Phelps; J L Johnson; T D Wilkins
Journal:  Nucleic Acids Res       Date:  1990-07-11       Impact factor: 16.971

4.  Molecular characterization of the Clostridium difficile toxin A gene.

Authors:  C H Dove; S Z Wang; S B Price; C J Phelps; D M Lyerly; T D Wilkins; J L Johnson
Journal:  Infect Immun       Date:  1990-02       Impact factor: 3.441

5.  Treatment of antibiotic-associated Clostridium difficile colitis with oral vancomycin: comparison of two dosage regimens.

Authors:  R Fekety; J Silva; C Kauffman; B Buggy; H G Deery
Journal:  Am J Med       Date:  1989-01       Impact factor: 4.965

Review 6.  Clostridium difficile: its disease and toxins.

Authors:  D M Lyerly; H C Krivan; T D Wilkins
Journal:  Clin Microbiol Rev       Date:  1988-01       Impact factor: 26.132

7.  Immunization of mice against tetanus with fragments of tetanus toxin synthesized in Escherichia coli.

Authors:  N F Fairweather; V A Lyness; D J Maskell
Journal:  Infect Immun       Date:  1987-11       Impact factor: 3.441

8.  Quantitative study of antibiotic-induced susceptibility to Clostridium difficile enterocecitis in hamsters.

Authors:  H E Larson; S P Borriello
Journal:  Antimicrob Agents Chemother       Date:  1990-07       Impact factor: 5.191

9.  The effects of Clostridium difficile crude toxins and toxin A on ileal and colonic loops in immune and non-immune rabbits.

Authors:  J M Ketley; T J Mitchell; D C Candy; D W Burdon; J Stephen
Journal:  J Med Microbiol       Date:  1987-08       Impact factor: 2.472

10.  Adjuvant activity of Escherichia coli heat-labile enterotoxin and effect on the induction of oral tolerance in mice to unrelated protein antigens.

Authors:  J D Clements; N M Hartzog; F L Lyon
Journal:  Vaccine       Date:  1988-06       Impact factor: 3.641

View more
  22 in total

1.  New method to generate enzymatically deficient Clostridium difficile toxin B as an antigen for immunization.

Authors:  H Genth; J Selzer; C Busch; J Dumbach; F Hofmann; K Aktories; I Just
Journal:  Infect Immun       Date:  2000-03       Impact factor: 3.441

2.  Development and evaluation of an ovine antibody-based platform for treatment of Clostridium difficile infection.

Authors:  April Roberts; Joanna McGlashan; Ibrahim Al-Abdulla; Roger Ling; Harriet Denton; Steve Green; Ruth Coxon; John Landon; Clifford Shone
Journal:  Infect Immun       Date:  2011-12-05       Impact factor: 3.441

Review 3.  Vaccines against Clostridium difficile.

Authors:  Rosanna Leuzzi; Roberto Adamo; Maria Scarselli
Journal:  Hum Vaccin Immunother       Date:  2014-03-17       Impact factor: 3.452

Review 4.  Antibodies for treatment of Clostridium difficile infection.

Authors:  David P Humphreys; Mark H Wilcox
Journal:  Clin Vaccine Immunol       Date:  2014-04-30

5.  Immunization with Bacillus spores expressing toxin A peptide repeats protects against infection with Clostridium difficile strains producing toxins A and B.

Authors:  Patima Permpoonpattana; Huynh A Hong; Jutarop Phetcharaburanin; Jen-Min Huang; Jenny Cook; Neil F Fairweather; Simon M Cutting
Journal:  Infect Immun       Date:  2011-04-11       Impact factor: 3.441

6.  A chimeric toxin vaccine protects against primary and recurrent Clostridium difficile infection.

Authors:  Haiying Wang; Xingmin Sun; Yongrong Zhang; Shan Li; Kevin Chen; Lianfa Shi; Weijia Nie; Raj Kumar; Saul Tzipori; Jufang Wang; Tor Savidge; Hanping Feng
Journal:  Infect Immun       Date:  2012-05-21       Impact factor: 3.441

7.  Toll-like receptor 5-dependent immunogenicity and protective efficacy of a recombinant fusion protein vaccine containing the nontoxic domains of Clostridium difficile toxins A and B and Salmonella enterica serovar typhimurium flagellin in a mouse model of Clostridium difficile disease.

Authors:  Chandrabali Ghose; Janneke M Verhagen; Xinhua Chen; Jian Yu; Yaoxing Huang; Olivia Chenesseau; Ciarán P Kelly; David D Ho
Journal:  Infect Immun       Date:  2013-04-01       Impact factor: 3.441

Review 8.  Update on Clostridium difficile infection.

Authors:  C S Alcantara; R L Guerrant
Journal:  Curr Gastroenterol Rep       Date:  2000-08

9.  Protective efficacy induced by recombinant Clostridium difficile toxin fragments.

Authors:  Rosanna Leuzzi; Janice Spencer; Anthony Buckley; Cecilia Brettoni; Manuele Martinelli; Lorenza Tulli; Sara Marchi; Enrico Luzzi; June Irvine; Denise Candlish; Daniele Veggi; Werner Pansegrau; Luigi Fiaschi; Silvana Savino; Erwin Swennen; Osman Cakici; Ernesto Oviedo-Orta; Monica Giraldi; Barbara Baudner; Nunzia D'Urzo; Domenico Maione; Marco Soriani; Rino Rappuoli; Mariagrazia Pizza; Gillian R Douce; Maria Scarselli
Journal:  Infect Immun       Date:  2013-05-28       Impact factor: 3.441

10.  C-terminal repeats of Clostridium difficile toxin A induce production of chemokine and adhesion molecules in endothelial cells and promote migration of leukocytes.

Authors:  Chiou-Yueh Yeh; Chun-Nan Lin; Chuan-Fa Chang; Chun-Hung Lin; Huei-Ting Lien; Jen-Yang Chen; Jean-San Chia
Journal:  Infect Immun       Date:  2007-12-26       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.